Cyclobenzaprine optimised release - Tonix Pharmaceuticals

Drug Profile

Cyclobenzaprine optimised release - Tonix Pharmaceuticals

Alternative Names: TNX-105

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator Krele Pharmaceuticals Inc
  • Developer Tonix Pharmaceuticals Holding Corp
  • Class Dibenzocycloheptenes; Muscle relaxants; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - Post-traumatic stress disorders

Highest Development Phases

  • Discontinued Post-traumatic stress disorders

Most Recent Events

  • 15 Nov 2010 Investigation in Post-traumatic stress disorder in USA (PO)
  • 15 Nov 2010 TNX 105 will be available for licensing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top